BRNS Earnings Barinthus Biotherapeutics plc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–24 of 24
| Q2 2026 | 2026-06-30 | -0.39 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.14 | 2026-04-30 | 10-Q |
| FY 2025 | 2025-12-31 | -1.64 | 2026-03-13 | 10-K |
| Q3 2025 | 2025-09-30 | -1.37 | 2025-11-07 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.01 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.49 | 2026-04-30 | 10-Q |
| FY 2025 | 2024-12-31 | -1.55 | 2026-03-13 | 10-K |
| Q3 2025 | 2024-09-30 | -1.04 | 2025-11-07 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.83 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.40 | 2025-05-07 | 10-Q |
| FY 2024 | 2023-12-31 | -1.91 | 2025-03-20 | 10-K |
| Q3 2024 | 2023-09-30 | -1.46 | 2024-11-06 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.10 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.48 | 2024-05-13 | 10-Q |
| FY 2023 | 2022-12-31 | 0.14 | 2024-03-20 | 10-K |
| Q3 2023 | 2022-09-30 | 0.69 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | 0.48 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | 0.07 | 2023-05-12 | 10-Q |
| FY 2022 | 2021-12-31 | -1.96 | 2023-03-24 | 10-K |
| Q3 2022 | 2021-09-30 | -1.58 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.89 | 2022-08-09 | 10-Q |
| Q1 2022 | 2021-03-31 | -1.90 | 2022-05-11 | 10-Q |
| FY 2021 | 2020-12-31 | -2.24 | 2022-03-25 | 10-K |
| Q3 2021 | 2020-09-30 | -0.92 | 2021-11-12 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.